If confirmed, [18F]PARP1‐inhibitor PET may serve as a biomarker to identify low‐grade ovarian cancer patients with unexpectedly high PARP1 expression, indicating potential sensitivity to PARP inhibitors, even if they do not have breast cancer gene (BRCA) mutations or homologous recombination deficiency. This evidence concerns the gene PARP1 and breast carcinoma.